PAIRIDEX 

Headquarters: St. Louis (BioGenerator Labs in the Cortex district) 

What it does: Pairidex is developing a novel droplet digital PCR platform for more accurate, personalized monitoring of blood cancer. 

The latest: Pairidex established operations just over one year ago. Since then, Pairidex has closed an oversubscribed pre-seed round, licensed the necessary IP from WashU, established a CLIA-certified laboratory, and completed its first commercial sale. 

Why you should watch it: Our mission is to reduce uncertainty in the treatment of blood cancer. The ability to closely monitor a cancer patient’s response to treatment is crucial for decision-making — ensuring that a treatment is working, quickly identifying a potential relapse, and stopping maintenance therapy if the disease has been eradicated. Unfortunately for many patients with blood cancer, current testing methods are limited by high cost or poor sensitivity. Pairidex’s highly sensitive, low limit of detection, and cost-effective technology improves clinical decision-making by allowing physicians to test patients more accurately and more often with a simple blood test. 

What’s next: Our team is currently laser-focused on completing the necessary regulatory requirements for our blood cancer detection test to be offered to patients in the clinic. We’re working hard to achieve this in 2025. We are also actively expanding our technology to address an even broader range of cancers. To make all this possible, we will be raising additional VC funding later this year.

More about Pairidex
Founded: 2023 
Founder: Dr. Andrew Young, Dr. Grant Challen & BioGenerator Ventures
No. of employees: 6
Capital raised: $1.09 million
Investors: BioGenerator Ventures, MTC and other undisclosed investors